Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germicide testing on surrogate devices supported by Olympus in comments on draft guidance.

This article was originally published in The Gray Sheet

Executive Summary

LIQUID CHEMICAL GERMICIDE TESTING WITH DEVICE SURROGATES SUPPORTED BY OLYMPUS in Aug. 20 comments to FDA. Commenting on FDA's December 1996 draft guidance for germicide 510(k)s, endoscope manufacturer Olympus America, Inc. says that "surrogates would enhance the standardization of simulated use testing by minimizing potential procedural variations and increasing the troubleshooting capability of the investigators."

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel